Figure 8.
ELISpot assay to evaluate T cell activity in spleens from tumor bearing mice treated with mVG161. BALB/c mice were subcutaneously implanted with 1 × 106 CT26 tumor cells into the lower right flank, followed by multiple injections of 5 × 106 PFU/mouse/day, for 5 consecutive days, of either mVG161, VG160, or PBS control. Mouse IFN-γ ELISpot assay was performed on splenocytes collected from CT26 tumor bearing mice at 5, 7, and 9 days post-injection and exposed to CT26 cells (results shown are from 5 days post treatment). Quantitative results are graphed with 2 mice per group. p values were computed using unpaired t-test. Error bars indicate SD.